Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2020 16:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
August 05, 2020 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
July 20, 2020 06:30 ET | Source: Assembly Biosciences, Inc.; BeiGene, Ltd.

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million upfront payment and is eligible to receive up...
July 09, 2020 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection

SOUTH SAN FRANCISCO, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
July 02, 2020 16:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
June 25, 2020 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection

SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
June 22, 2020 08:45 ET | Source: Assembly Biosciences, Inc.

Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
June 18, 2020 16:01 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

-- Process to explore strategic alternatives underway -- SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology...
June 01, 2020 16:18 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
May 27, 2020 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Management Transition

-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology -- -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire -- SOUTH SAN FRANCISCO,...